💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Viyash Scientific Limited, formerly SeQuent Scientific Limited, is an India-based integrated pharmaceutical company with a global footprint, operating in the domains of animal health (active pharmaceutical ingredients (APIs), and finished dosage formulations) and analytical…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent business, trading cheap versus its own history.
Sequent Scientific is scored on the pharma / healthcare framework. It keeps a slim 6.5% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.44× reported profit. Free cash flow is worth about 2.4% of its market value.
Book value itself has compounded 61%/yr — the hallmark of a genuine compounder. Return on equity is a weak 7.1%. In the latest quarter profit grew 19% versus the prior quarter.
At 56× earnings, the stock sits at the 13th percentile of its own 1.6-year range — the cheap end of where it has historically traded. Today's price implies ~18%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 37.98 | — | — |
| P/B | 3.6 | 4.1 | better |
| EV/EBITDA | 14.72 | 19.33 | better |
| ROE | 7.07 | — | — |
| ROCE | 13.01 | 14.41 | worse |
| ROA | 5.77 | 1.64 | better |
| Quick Ratio | 1.53 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
34% CAGR over 3 years — high-growth territory. Growth is decelerating — latest year grew slower than the year before.
2 of the 4 years shown had a loss — profitability is inconsistent. The latest year saw a +1325% swing — check if it's a one-off or structural.
Operating margin has expanded from -10% to 10% — the business is keeping more of each rupee earned. The gap between operating and net margin is widening — interest or tax costs are rising.
ROE at 7% — modest; the capital isn't working hard. Capital efficiency improving — ROE up 23pp across the window.
EPS has grown every year — each share earns more than the last, consistently. Profit grew faster than EPS (1325% vs 657%) — share dilution is eroding per-share value. 657% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.4× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Run-rate stepping up — recent quarters average 9% above earlier ones.
Profit jumped 19% QoQ — check if this is operating leverage or a one-off item.
How today's P/E compares to the stock's own historical range. Dashed line = the 1.6y median.
Promoters at 49.2% — dispersed ownership; institutional flows drive the stock. Promoters reduced 12.2pp over 4 quarters — watch whether this is planned divestment or pledge invocations.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.